Squarepoint
ATNM icon

Squarepoint’s Actinium Pharmaceuticals ATNM Stock Holding History

Squarepoint’s Portfolio ATNM Stock Details ATNM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-65,730
Closed -$89.4K – 4254
2025
Q4 		$89.4K Buy
+65,730
New +$95.9K ﹤0.01% 4052
2025
Q1 		– Sell
-183,262
Closed -$231K – 4556
2024
Q4 		$231K Buy
183,262
+37,159
+25% +$57.7K ﹤0.01% 4360
2024
Q3 		$275K Buy
146,103
+98,007
+204% +$387K ﹤0.01% 3511
2024
Q2 		$356K Buy
+48,096
New +$396K ﹤0.01% 3320
2023
Q3 		– Sell
-10,285
Closed -$76.3K – 3767
2023
Q2 		$76.3K Sell
10,285
-18,860
-65% -$160K ﹤0.01% 3398
2023
Q1 		$275K Buy
+29,145
New +$308K ﹤0.01% 2626
2020
Q3 		– Sell
-16,188
Closed -$171K – 2479
2020
Q2 		$171K Buy
+16,188
New +$123K ﹤0.01% 1870
2019
Q3 		– Sell
-757
Closed -$6K – 2331
2019
Q2 		$6K Sell
757
-80
-10% -$804 ﹤0.01% 2323
2019
Q1 		$12K Hold
837
– – ﹤0.01% 2096
2018
Q4 		$10K Sell
837
-1,703
-67% -$29K ﹤0.01% 1884
2018
Q3 		$57K Buy
2,540
+1,797
+242% +$36.6K ﹤0.01% 1918
2018
Q2 		$14K Buy
+743
New +$9.41K ﹤0.01% 1710
2015
Q3 		– Sell
-1,737
Closed -$138K – 405
2015
Q2 		$138K Buy
+1,737
New +$148K 0.04% 388

Other funds holding ATNM

VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
GS
Gagnon Securities New York $433M AUM 29.08% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Squarepoint's ATNM Position: Q1 2026 in Review

Squarepoint sold out of Actinium Pharmaceuticals (ATNM) in Q1 2026, closing a stake of 65,730 shares — an estimated $89.4K sold.

Squarepoint first reported a position in ATNM in Q2 2015 and held it in 13 quarters. The position peaked at $356K in Q2 2024. 54 funds tracked by Wall St. Rank hold ATNM as of Q1 2026.

  • Squarepoint reported no remaining Actinium Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • Squarepoint sold 65,730 Actinium Pharmaceuticals shares in Q1 2026, an estimated $89.4K.
  • Squarepoint first reported a position in Actinium Pharmaceuticals in Q2 2015 and held it in 13 quarters.
  • Squarepoint's Actinium Pharmaceuticals position peaked at $356K in Q2 2024.
  • 54 funds tracked by Wall St. Rank held Actinium Pharmaceuticals as of Q1 2026.

Based on Squarepoint's 13F filing for Q1 2026, filed 15 May 2026.